Skip to content
Baret News – Lifestyle
Author:
Ethris GmbH
Ethris Reports Positive Topline Phase 2a Data for Nasal mRNA Candidate ETH47 in Asthma Patients Challenged with Rhinovirus
November 5, 2026
Ethris and EIB sign €30M financing under HERA Invest to advance further clinical development of broad-spectrum nasal antiviral
September 10, 2026